medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 2

<< Back Next >>

Ann Hepatol 2015; 14 (2)

The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis

Zhang X, Liu L, Zhang M, Gao S, Du Y, An Y, Chen S

Language: English
References: 40
Page: 150-160
PDF size: 129.78 Kb.


ABSTRACT

Background. The effectiveness of nucleoside analogue (NA) treatment in patients with chronic hepatitis B (CHB) -associated liver failure is still controversial. Severe lactic acidosis has been reported during entecavir (ETV) treatment in patients with impaired liver function. Aim. To investigate the rescuing efficacy and safety of ETV in patients with CHB-associated liver failure. Material and methods. A literature search was carried out to collect articles dated up to December, 2013 on ETV therapy for patients with CHB-associated liver failure. Risk ratio (RR) and mean difference (MD) were used to measure the effects. Survival rate was used as the primary efficacy measure. The safety of ETV was assessed. Results. Six randomized controlled trials were selected. The overall analysis revealed ETV significantly improved survival at 4 weeks (RR = 1.35; 95% CI [1.16, 1.57]; p ‹ 0.0001), 8 weeks (RR = 1.33; 95% CI [1.07, 1.64]; p = 0.009), 12 weeks (RR = 1.68; 95% CI [1.24, 2.28]; p = 0.0008). Pooled data also showed beneficial effects of antiviral therapy compared with control for HBV DNA negative change (RR = 5.35; 95% CI [2.06, 13.88]; p = 0.0006), TBIL and PTA improvement (TBIL: MD = -69.36; 95% CI [-134.37, -4.36]; p = 0.04. PTA: MD = 16.26; 95% CI [8.59, 23.94]; p ‹ 0.0001). No adverse effect was identified in the examined studies. Conclusion. Our results showed that antiviral therapy with ETV improved the short-term survival of patients with CHB-associated liver failure. In addition, ETV was well tolerated during the treatment period. Further studies are still needed to strengthen these results.


REFERENCES

  1. Xie F, Yan L, Lu J, Zheng T, Shi C, Ying J, Shen R, et al. Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure: meta-analysis. PLoS One 2013; 8: e54773.

  2. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.

  3. Li LJ. 13th Asia-Pacific congress of clinical microbiology and infection consensus guidelines for diagnosis and treatment of liver failure. Hepatobiliary and Pancreatic Diseases International 2013; 12: 346-54.

  4. Association CM. Guidelines for diagnosis and treatment of liver failure. Chin J Clin Infect Dis 2012; 5: 321-7.

  5. Gao ZL, Zhang XH. The treatment of complications of liver failure. Zhonghua Gan Zang Bing Za Zhi 2010; 18: 811-13.

  6. Mochida S. Indication criteria for liver transplantation for acute liver failure in Japan. Hepatol Res 2008; 38(Suppl. 1): S52-S55.

  7. Steadman RH, Van Rensburg A, Kramer DJ. Transplantation for acute liver failure: perioperative management. Curr Opin Organ Transplant 2010; 15: 368-73.

  8. Liver EAFTSOT. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.

  9. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176-82.

  10. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62-72.

  11. Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, Prabhakar B, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat 2012; 19: 732-43.

  12. Sun LJ, Yu JW, Zhao YH, Kang P, Li SC. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure. J Gastroenterol Hepatol 2010; 25: 583-90.

  13. Chen J, Han JH, Liu C, Yu RH, Li FZ, Li QF, Gong GZ. Shortterm entecavir therapy of chronic severe hepatitis B. Hepatobiliary Pancreat Dis Int 2009; 8: 261-6.

  14. Cui YL, Yan F, Wang YB, Song XQ, Liu L, Lei XZ, Zheng MH, et al. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig Dis Sci 2010; 55: 2373-80.

  15. Wong VW, Wong GL, Yiu KK, Chim AM, Chu SH, Chan HY, Sung JJ, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 2011; 54: 236-42.

  16. Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, Silva JH, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatology International 2009; 3: 269-82.

  17. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, Gane E, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatology International 2012; 6: 531-61.

  18. Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, Sarrazin C. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001-06.

  19. Association CM. National viral hepatitis control programme. Chin J Hepatol 2000; 8: 324-29.

  20. Association CM. Guidelines for chronic hepatitis B (2010). Chinese Hepatology 2011; 16: 2-16.

  21. Haimin Y, Yan W, Na J. Baraclude for Treatment of 55 Patients with Chronic Severe Hepatitis B. JPMT 2008; 15: 1100-01.

  22. Yuxiang G. Clinical Observation of Entecavir in Treatment of Patients with Chronic Severe Hepatitis B. Chin J Prev Contr Chron Non-commun Dis 2008; 16: 289-90.

  23. Biao W. The Effects of Entecavir Treament on the Shortterm Prognosis of the Severe Chronic Hepatitis B. Sun Yat- Sen University 2008.

  24. Zhaohui W. Clinical Observation of Entecavir Treatment for Severe Chronic Hepatitis B. Guide of China Medicine 2011; 9: 283-5.

  25. Dan L. Prognosis of Entecavir to Treat Severe Chronic Hepatitis B. Health Horizon 2011; 5: 21-2.

  26. Lei F. The treatment effect of enticavir on chronic severe hepatitis B. Medical Frontier 2013; 8: 7-8.

  27. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000; 32: 734-9.

  28. Wang J, Jiang D, Zhang H, Lv S, Rao H, Fei R, Wei L. Proteome responses to stable hepatitis B virus transfection and following interferon alpha treatment in human liver cell line HepG2. Proteomics 2009; 9: 1672-82.

  29. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-75.

  30. Zhao Z, Han T, Gao Y, Gao Y, Zhang Y, Wu Z. Analysis on the predisposing cause and outcome of 289 cases of hepatitis B patients complicated with chronic or acute liver failure. World J Gastroenterol 2009; 17: 3269-72.

  31. Zhang L, Hao CQ, Liu JF, Wang M. Meta-analysis of the short-term effects of lamivudine treatment for severe chronic hepatitis B. Virol J 2013; 10: 134.

  32. Tillmann HL, Zachou K, Dalekos GN. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? Liver Int 2012; 32: 544-53.

  33. Keating GM. Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. Drugs 2011; 71: 2511-29.

  34. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012; 57: 442-50.

  35. Sadler MD, Coffin CS, Lee SS. Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis. Expert Opin Pharmacother 2013; 14: 1363-9.

  36. Ma K, Guo W, Han M, Chen G, Chen T, Wu Z, Yang D, et al. Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: Establishment of a novel logistical regression model. Hepatology International 2012; 6: 735-43.

  37. Chen T, He Y, Liu X, Yan Z, Wang K, Liu H, Zhang S, et al. Nucleoside analogues improve the short-term and longterm prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure. Clin Exp Med 2012; 12: 159-64.

  38. Lin B, Pan CQ, Xie D, Xie J, Xie S, Zhang X, Wu B, et al. Entecavir improves the outcome of acute-on-chronic liver failure due to the acute exacerbation of chronic hepatitis B. Hepatology International 2013; 7: 460-7.

  39. Lu GF, Tang FA, Zheng PY, Yang PC, Qi YM. Entecavir up-regulates dendritic cell function in patients with chronic hepatitis B. World J Gastroenterol 2008; 14: 1617-21.

  40. Yan Y, Mai L, Zheng YB, Zhang SQ, Xu WX, Gao ZL, Ke WM. What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients? World J Gastroenterol 2012; 18: 4604-09.




2020     |     www.medigraphic.com